Summary

  • Quanome’s 1 October preliminary Form S-3/A registers up to $120 million of possible securities offerings; it does not show a completed sale, received proceeds or money allocated to servers.
  • Its separate Compal agreement covers 32 GPU-server units for about $18.8 million, with 20% due after purchase-order acceptance and 80% before shipment, subject to the agreement’s conditions.
  • The prospectus says the new AI-compute activity had no executed customer contracts or revenue as of 1 October. The public record therefore leaves the funding-to-demand sequence open; it does not establish either a current cash shortfall or an inability to perform.

The timing matters more than the headline comparison. Quanome’s preliminary prospectus is labelled subject to completion and is Pre-Effective Amendment No. 3 to its registration statement. It lists common and preferred stock, debt securities, warrants, rights and units, up to $120 million in aggregate. Any proceeds and their use are to be described in a later prospectus supplement. The filing supplies no completed offering, instrument mix, sale price, net proceeds or allocation to the Compal purchase.

The purchase is more concrete, but still conditional. In a 21 September Form 8-K, Quanome said it had signed the purchase-and-sale agreement and related order with Compal Electronics on 16 September for 32 GPU server units at an approximate total of $18.8 million. The summary says 20% follows purchase-order acceptance and the remaining 80% is payable before shipment, subject to delivery and other terms. On the rounded headline price those shares are roughly $3.76 million and $15.04 million; they are arithmetic, not separately quoted invoices. The filing does not name the designated US data-centre site.

Nor does the 8-K supply the whole contract. It says its description is incomplete and that the agreement itself was intended for the 10-Q for the quarter ended 30 September. It mentions inspection and acceptance, warranties, non-conformance remedies and certain termination or refund rights, without publishing their full triggers, dates or mechanics. Supplier production, shipment, product registration and other conditions remain distinct from payment and from an operating service.

The new service has not yet supplied demand evidence. The S-3/A says Quanome’s AI-compute and managed-inference work began in September and, as of the prospectus date, had no executed customer contracts or revenue. This is not a company-wide zero-revenue statement: pharmaceutical distribution remains an established business. A 23 September release targeted a first US hub in Q4 2026, subject to delivery and deployment, and said further investment would follow customer demand, available funding and operating readiness. That is a target, not a completed launch.

Quanome’s 25 September 10-K reports cash of $670,281 at 30 June, before the 16 September order. It also reports a $9.4 million net loan receivable and substantial doubt language from its auditor. Those dated disclosures warrant attention but cannot be treated as the company’s cash position on the order date or today. The 10-K does not prove a present funding gap for this purchase.

The next evidence is a sequence, not a single “AI hub” milestone: an effective registration and any sale-specific supplement; cash proceeds and instrument terms; purchase-order acceptance and payment; production, shipment and delivery; then signed customers, service availability and collections. Quanome controls its financing and customer disclosures; Compal controls supplier-side production and delivery; the data-centre host is unnamed; future customers control demand. Until the full agreement and later filings clarify remedies, timing and funding, idle capacity, dilution or debt are scenarios to test—not outcomes established by the filings.

Sources: 1 October Form S-3/A; 21 September Form 8-K; 25 September Form 10-K; 23 September company release.